Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients by Martins-de-Souza, D et al.
Identiﬁcation of proteomic signatures associated with
depression and psychotic depression in post-mortem
brains from major depression patients
D Martins-de-Souza
1,2, PC Guest
1, LW Harris
1, N Vanattou-Saifoudine
1, MJ Webster
3, H Rahmoune
1 and S Bahn
1,4
Majordepressivedisorder (MDD)is aleadingcauseofdisabilityworldwideandresultstragicallyinthe lossofalmost onemillion
lives in Western societies every year. This is due to poor understanding of the disease pathophysiology and lack of empirical
medical tests for accurate diagnosis or for guiding antidepressant treatment strategies. Here, we have usedshotgun proteomics
in the analysis of post-mortem dorsolateral prefrontal cortex brain tissue from 24 MDD patients and 12 matched controls. Brain
proteomes were pre-fractionated by gel electrophoresis and further analyzed by shotgun data-independent label-free liquid
chromatography-mass spectrometry. This led to identiﬁcation of distinct proteome ﬁngerprints between MDD and control
subjects. Some of these differences were validated by Western blot or selected reaction monitoring mass spectrometry. This
included proteins associated with energy metabolism and synaptic function and we also found changes in the histidine triad
nucleotide-binding protein 1 (HINT1), which has been implicated recently in regulation of mood and behavior. We also found
differential proteome proﬁles in MDD with (n¼11) and without (n¼12) psychosis. Interestingly, the psychosis ﬁngerprint
showedamarkedoverlaptochangesseeninthebrainproteomeofschizophreniapatients.Theseﬁndingssuggestthatitmaybe
possible to contribute to the disease understanding by distinguishing different subtypes of MDD based on distinct brain
proteomic proﬁles.
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Introduction
Major depressive disorder (MDD) is a serious psychiatric
condition affecting approximately 10% of the world population
with a lifetime prevalence of 17%.
1 The effects of MDD are
wide-ranging, including a negative impact on families, work
and relationships, and has been associated with debilitating
co-morbiditiessuchasgeneralillhealth,substanceabuseand
anxiety disorders. Together, these factors contribute to an
enormous signiﬁcant ﬁnancial burden on the healthcare
services.
2 In addition, MDD subjects account for 60% of
suicides in the United States.
3 Although some molecular
aspects of MDD have been identiﬁed, such as hypothalamic–
pituitary–adrenal axis dysfunction,
4 effects on memory
5 and
volume reduction of certain brain regions such as hippocam-
pus
6andprefrontal cortex,
7theunderlyingpathophysiologyof
this disorder has only been partially elucidated. The associa-
tion between inﬂammation and MDD has been supported by
the fact that treatment of hepatitis C and certain cancer
patients with interferon-alpha,
8,9 frequently induces depres-
sive symptoms as side-effects. In addition, MDD is also
associated with auto-immune diseases
10 and metabolic
disorders,
11 and several studies have shown that the efﬁcacy
of antidepressants may be partly attributable to their anti-
inﬂammatory properties.
12 As a consequence, currently
available antidepressant medications often show only med-
ium efﬁcacy and can have serious side-effects.
13 Therefore, it
isimportanttoincreaseourunderstandingofthephysiological
factors underlying this condition before more effective
medications can be developed.
Studies of MDD are complicated by the fact that it is a
systemic, multifactorial disorder. Current hypotheses suggest
that MDD most likely arises from complex interactions
between genetic predisposition,
14 disturbance of key mole-
cular pathways including neurotransmitter systems and
synaptic plasticity,
4 along with the impact of environmental
factors such as stressful life events.
15,16 Therefore, an
increased understanding of this disorder is likely to be gained
by application of molecular proﬁling analyses of relevant brain
regions using approaches such as transcriptomics,
17,18
lipidomics
19 and proteomics.
20 Of these platforms, proteo-
mics may be the most appropriate for studies of psychiatric
conditions considering that it is better suited for capturing the
dynamic nature of perturbed biological systems.
20,21
MDD patients can present with a great variety of symptoms
including low mood, low self-esteem, loss of interest or
pleasure in normally enjoyable activities and melancholia.
MDD patients may also present with severe psychotic
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www.nature.com/tpsymptoms, including delusions and hallucinations. Similar
symptoms are often observed, for example, in schizophrenia
albeit with subtle differences. Therefore, the identiﬁcation of
symptom-related potential biomarker candidates
22 could be
useful in combination with the existing clinical assessment for
more accurate classiﬁcation of MDD patients and also to
provide a biochemical comprehension of the molecular
processes involved. These could be useful not only for
potential diagnostic purposes but also to provide a molecular
means of distinguishing patients to facilitate much-needed
personalized medicine strategies.
With this in mind, we have carried out shotgun proteome
analyses as represented in Supplementary Material 1 on
post-mortem dorsolateral prefrontal cortex (DLPFC) tissue
fromMDDpatients.Featuressuchasvolumereduction
7and
reduced activation
23 have previously suggested that effects
on this brain region are associated with MDD.
24 We
used label-free liquid chromatography mass spectrometry
in data-independent mode (LC-MS
E)t oa n a l y z eD L P F C
tissue from 24 MDD patients and 12 control subjects. The
DLPFC is known to be involved in executive and intellectual
functions, integration of sensory and mnemonic information
and in working memory.
25 Additionally, we have re-eval-
uated the data considering those MDD patients who
presented with (n¼11) or without (n¼12) psychotic
symptoms, in an attempt to identify a MDD psychosis-
speciﬁc signature.
Materials and methods
Clinical samples. DLPFC tissues (Brodmann area 9) were
collected post-mortem and frozen from MDD patients
(n¼24), either with psychosis (n¼11) or without psychosis
(n¼12) plus matched control subjects (n¼12) by the
Stanley Medical Research Institute (Bethesda, MD, USA).
One of the MDD patients could not be deﬁned as psychotic or
not. The diagnosis of MDD had been given ante-mortem.
Consent was obtained by questionnaire-based telephone
interview and signed by the interviewer and a witness. The
Institutional Review Board at the Uniformed Services
University of Health Sciences determined that the
procedure was exempt from federal and state regulations
governing human research, as specimens were obtained
from cadavers and anonymized with respect to personal
information. General patient information is given in Table 1
and detailed information in Supplementary Material 2.
Sample and proteome preparation. Tissue samples
(20mg) were homogenized individually in 100mlo f7 M urea,
2 M thiourea, 4% CHAPS, 2% ASB-14 and 70mM DTT, as
described previously,
26 using the Sample Grinding Kit (GE
Healthcare, Little Chalfont, Bucks, UK). Samples were cen-
trifuged for 10min at 16000 g, the supernatants were
collected and protein concentrations were determined using
the Bradford dye-binding assay (Sigma, Poole, Dorset, UK).
For enhancing proteome coverage, SDS–polyacrylamide gel
electrophoresis (SDS-PAGE) pre-fractionation was used for
separation of proteins according to apparent molecular size.
Extracted protein samples (15mg) were diluted in SDS-PAGE
sample loading buffer (2% w/v SDS, 100mM Tris (pH 6.8),
10% glycerol, 100mM DTT and 0.001% w/v bromophenol
blue). Samples were heated for 5min at 951C before elec-
trophoresis on NuPAGE 4–12% bis-tris polyacrylamide gels
(Invitrogen, Paisley, UK). Protein bands were visualized using
Coomassie blue staining. Each lane containing stained protein
bands was sliced in the horizontal direction to produce four
sections corresponding to different apparent molecular weight
ranges. Each gel section was then subjected to trypsin
digestion in situ as described previously,
27 and resulting
peptide mixtures were lyophilized.
Nano-high-performance liquid chromatography—mass
spectrometry analyses. Lyophilized peptides were dissolved
in 0.1% formic acid and 0.5mg injected in duplicate into a
nanoUltra-Performance Liquid Chromatography instrument
containing a BEH-130 C18 column (75mm 200mm) at a
ﬂow rate of 0.3mlmin
–1 connected online to a Q-TOF Premier
Mass Spectrometer (Waters Corporation, Manchester, UK).
The following gradient was applied over 140min comprised of
solvent A (0.1% aqueous formic acid) and solvent B
(acetonitrile with 0.1% formic acid): 97/3% (A/B) to 70/30%
in 90min; 70/30 to 10/90% in 25min; 10/90 to 3/97% in 5min;
10min at 3/97%; returning to the initial condition in 1min.
Eluted peptides were measured in MS
E mode (data-independent
Table 1 Demographic information for the brain tissue samples used in the study
Control All MDD MDD-P MDD-NP Signiﬁcance Signiﬁcance
t-test for MDD x
CTRL (P-value)
ANOVA for MDD-P x
CTRL x MDD-NP ( P-value)
Sample size 12 24 12 12
Age 47±12 42±11 40±11 43±10 0.38 0.30
Postmortem interval 25.3±10.6 29.7±12.4 33.1±11 23.6±6.7 0.44 0.12
Refrigerator interval 7.4±5.4 7.9±6.3 7.2±3.9 8±8.2 0.80 0.94
Brain pH 6.6±0.2 6.7±0.2 6.6±0.2 6.7±0.1 0.44 0.12
Fisher’s exact test
Gender (male/female) 8/4 13/11 5/6 7/5 0.57 0.41 (MDD-P x CTRL)
0.99 (MDD-NP x CTRL)
0.68 (MDD-P x MDD-NP)
Abbreviations: ANOVA, analysis of variance; CTRL, control; MDD, major depressive disorder.
Values are mean ±s.d. MDD patients have been considered as one group (All MDD) or separately according to the presence of psychosis (MDD-P and MDD-NP).
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28 for data
processing. Analysis of the resulting chromatograms/mass
spectra and database searching were performed using the
ProteinLynx Global Server (PLGS) v.2.4 (Waters Corp.).
Firstly, raw data were processed and chromatograms aligned
in time. Aligned peaks were extracted and abundance
measurements obtained by integration of time, mass/charge
(m/z) and intensity volumes, with normalization to the total ion
current. Data were searched against the SwissProt human
database (version 57.4; http://www.uniprot.org/) and also
against a randomized database to exclude false-positives.
The maximum false identiﬁcation rate was set to 4% and
peptides had to be detected in 470% of samples to ensure
biological reproducibility. The criteria for protein identiﬁcations
were set at a minimum of three ion fragments per peptide,
seven ion fragments per protein and one peptide per protein.
However, we only considered for differential expression
analyses proteins identiﬁed by at least two peptides. Modi-
ﬁcations considered were carbamidomethylation of cysteines
and oxidation of methionine.
Quantitative protein expression and statistical analyses
were performed using the Rosetta Elucidator system
v.3.3.0.1.SP3.19 (Rosetta Inpharmatics, Seattle, WA, USA)
and processed data from PLGS analysis. We established a
fold change cutoff of ±1.15 based on the following facts: (1)
coefﬁcient of variation calculated for all identiﬁed proteins was
0.18±0.3 (mean±s.d.); (2) label-free proteomics has been
shown to underestimate fold changes,
29 which is supported
by the fact that a protein with a fold change of 1.13 was
validated by Western blot analysis revealing a 1.47-fold
change.
Statistical analyses. Differences in protein expression
between MDD patients and controls were accessed using
Wilcoxon signed-rank test, as the data were not assumed to
be normally distributed. Only differences with a Po0.05 were
considered signiﬁcant. False discovery rate (FDR) was
calculated according to Benjamini and Hochberg.
30 No
adjustments were made for multiple comparisons in order
to not exclude possible true positives.
31 This approach will
lead to fewer errors of interpretation as proteomic data are
not necessarily random but can be physiologically inter-
dependent observations. Nevertheless, a FDR threshold of
approximately 0.4 and a fold change cutoff of 15% for the
shotgun proteome analyses was established.
Although groups are matched for demographic variables
(Table 1), the inﬂuence of gender, age, alcohol abuse,
smoking, post-mortem interval and refrigeration interval on
the data were accessed by using principal component
analysis (PCA) as previously described.
32 The PCA results
are presented in Supplementary Material 3. Differentially
expressed proteins were not found to be correlated to
demographics variables.
Selected reaction monitoring. Quantitative differences in
the levels of histidine triad nucleotide-binding protein 1
(HINT1) and synaptosomal-associated protein 25
(SNAP25) were validated using whole tissue lysates by
selected reaction monitoring (SRM) mass spectrometry.
Three SRM transitions of the HINT1 peptides ‘IIFEDDR’,
‘HISQISVAEDDDESLLGHLMIVGK’ and ‘MVVNEGSDGGQ
SVYHVHLHVLGGR’ were analyzed, as well as three
SRM transitions of the SNAP25 peptides ‘NELEEMQR’,
‘AWGNNQDGVVASQPAR’ and ‘IEEGMDQINK’. Peptides
were selected based on identiﬁcation in the LC-MS
E dataset
with a high spectral quality, and if those peptides were pro-
teotypic, which means an experimentally observable peptide
that uniquely identiﬁes a speciﬁc protein or protein isoforms.
33
Samples (0.2mg) were prepared exactly like for LC-MS
E
analyses. Whole digested lysates were injected in duplicate
into an identical LC system, as above, coupled to a Xevo
triple-quadrupole mass spectrometer (Waters). For separa-
tion of peptides, the following 48mingradient was applied: 97/
3% (A/B) to 60/40% B in 30min; 60/40 to 15/85% in 2min;
5min at 15/85%; returning to the initial condition in 1min.
Eluted peptides were measured in SRM mode using an
electrospray voltage of 22kV and a cone voltage of 35V. All
SRM functions had a 2min window of the predicted retention
time and the scan time was 20 milliseconds. The collision
energy for each transition was optimized using Skyline
software
34 based on the equation: CE¼0.034*m/zþ3.314.
Acquired data were processed using TargetLynx (Waters).
Differences in protein levels between MDD and controls were
determined using Student’s t-tests considering Po0.05 as
signiﬁcant.
Western blot. Quantitative differences in the levels of
amphiphysin (AMPH) and growth-associated protein 43
(GAP43) were assessed for validation of LC-MS
E ﬁndings
by Western blot analyses due to their involvement in
synapses. Total tissue lysates from MDD and controls were
arranged in randomized order such that each of the groups
were represented on both gels. For each sample, 20mg total
protein was electrophoresed using pre-cast Novex 10–20%
Tricine polyacrylamide gels (Invitrogen) at 125V for 60min,
followed by semi-dry transfer to Immobilon-FL poly-
vinyldiphenyl ﬂuoride membranes (Millipore, Watford, UK).
The membranes were incubated in a 1:1 mixture of Odyssey
blocking buffer (Li-COR Biosciences, Cambridge, UK) and
phosphate-buffered saline containing 0.1% Tween-20 for 1h
at room temperature. Membranes were then incubated
overnight at 41C with the following primary antibodies (both
from Abcam, Cambridge, UK): anti-amphiphysin (1:2000)
and anti-GAP-43 (1/5000). Membranes were washed in Tris-
buffered saline containing EDTA for 30min, in phosphate-
buffered saline for 2 5min and then for 1h at room
temperature with the appropriate IR dye-conjugated
secondary antibodies (1:7500 for secondary rabbit antibody
and 1:15000 for secondary mouse antibody Li-COR
Biosciences) in blocking buffer. Immunoreactive protein
bands were visualized using the Odyssey Infra-red imaging
system (Li-COR Biosciences) and the integrated intensities
of the bands measured. Values outlying by more than two
standard deviations from the mean were excluded from the
analysis. Differences in protein levels between MDD and
controls were determined using Student’s t-tests considering
Po0.05 as signiﬁcant.
ATP assay. In order to validate the differential expression of
several oxidative phosphorylation protein subunits, ATP
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according the manufacturers’ instructions (BioVision, San
Francisco, CA, USA). Differences in ATP levels per 5mgo f
brain tissue between MDD and controls were determined
using Student’s t-tests considering Po0.05 as signiﬁcant.
Classiﬁcation of differentially expressed proteins.
Differentially expressed proteins in MDD DLPFC were
classiﬁed according to their biological pathways and sub-
cellular localization using the Human Protein Reference
Database (http://www.hprd.org) and KEGG database
(www.genome.jp/kegg). For interpretation of the functional
signiﬁcance of differentially expressed proteins, the asso-
ciated SwissProt accession numbers were uploaded into the
Ingenuity Pathways Knowledgebase (IPKB) (www.ingenuity.
com) and these were analyzed to identify potential interactions
between these proteins and other proteins in the IPKB.
Results
Shotgun proteomics results. The shotgun LC-MS
E
strategy for protein proﬁling of post-mortem DLPFC
samples from MDD (n¼24) and control subjects (n¼12) is
outlined in Supplementary Material 1. This resulted in
identiﬁcation of 18422 unique peptides in the 36 analyzed
samples, which led to identiﬁcation of 1422 non-redundant
proteins. From these, 526 proteins were identiﬁed with a
minimum of two distinct peptides and detected at least in
475% of samples. Overall, 35 of these were discarded,
as they were keratin and trypsin contaminations. Therefore,
491 proteins were considered for differential analyses. These
proteins, their peptides and mass spectra data are
deposited at the PRIDE database
35 (http://www.ebi.ac.uk/
pride; accession number: 15310). There were no signiﬁcant
differences between MDD patients and controls with regards
to gender, age, post-mortem and refrigeration interval and
brain pH (Table 1). In addition, PCA of the data showed no
overt effects of any of these parameters (Supplementary
Material 3).
Proteome differences between MDD and control
subjects. Comparing all MDD patient samples to controls,
signiﬁcant differences (Po0.05; Wilcoxon test) in protein
levels were observed for 39 proteins with a fold change cutoff
of ±1.15 and a FDR of approximately 0.4 although most
were approximately 0.350 (Table 2). No adjustment for
FDR was used
31 as described in material and methods
section. AMPH is the only exception for the fold change
cutoff as it has been validated by Western Blot. Two of these
proteins were decreased and 37 increased in MDD patients
compared with controls. These proteins were classiﬁed
according to their biological processes and cellular
localization. The major pathways that are associated with
MDD were metabolic/energy pathways (32%) and transport
of molecules (22%) (Supplementary Material 4A). The
majority of the differentially expressed proteins (72%) were
identiﬁed as cytoplasmic, and 13% were membrane-
associated proteins (Supplementary Material 4B). We also
identiﬁed several proteins such as proﬁlin 1 and 2 (PFN1 and
PFN2), SNAP25 and gamma aminobutyric acid receptor-
associated protein like 2 (GABARAPL2) that are involved in
synaptic transmission (Figure 1). Also, some of these
proteins have been previously associated with other
neurological or psychiatric conditions such as Huntington’s
disease (27%), schizophrenia (18%) and Alzheimer’s
disease (3%) (Supplementary Material 5).
Proteome differences in MDD patients with and without
psychosis. Shotgun LC-MS
E analysis of MDD patients with
psychosis (MDD-P) and without psychosis (MDD-NP)
showed signiﬁcant differences (Po0.05; Wilcoxon test) in
proteomic proﬁles with an FDR of approximately 0.4.
Proteomic comparison of MDD-NP patients (n¼12) with
control subjects (n¼12) led to identiﬁcation of 18 altered
proteins. However, comparison of MDD-P patients (n¼11)
with controls resulted in identiﬁcation of 36 altered proteins
and direct comparison of the MDD-P and MDD-NP
proteomes resulted in identiﬁcation of 30 signiﬁcantly
different proteins. All of the differentially expressed proteins
associated with the categories above are listed in Table 3
and classiﬁed according to their biological processes and
cellular localization (Figure 2).
The overlapping proteins across these different compar-
isons are shown in Figure 3. Five proteins (cystatin C (CST3),
fatty acid-binding protein (FABP3), rho-related GTP-binding
protein (RHOC), gamma synuclein (SNCG) and peptidylprolyl
isomerase A (PPIA)) were changed in common between the
MDD-P and MDD-NP patients relative to controls (Figure 3a).
A total of 13 proteins were altered speciﬁcally in the MDD-NP
subjects, including the HINT1 and the mitochondrial ATP
synthase subunits b and e (ATP5F1 and ATP5I). Overall, 31
proteins were altered speciﬁcally in the MDD-P patients
including the synaptic vesicle-related proteins AMPH and
SNAP25. Direct comparison of the MDD-P and MDD-NP
proteomes resulted in identiﬁcation of 25 altered proteins,
which were not found in either of the MDD-P vs control or
MDD-NP vs control comparisons (Figure 3b). These proteins
included ADP-ribosylation factor 1 and 3 (ARF1 and ARF3),
synaptotagmin2(SYT2)andstress-inducedphosphoprotein1
(STIP1). Moreover, there was no overlap of this signature with
that found in the total MDD vs control comparison.
Comparison of these datasets with those obtained from
previous proteomic studies of post-mortem brain tissue from
schizophrenia patients
36–38 showed a marked overlap be-
tween the MDD-P and schizophrenia proteomes (Figure 3a).
Also, the psychosis-speciﬁc ﬁngerprint obtained by direct
comparison of MDD-P and MDD-NP subjects showed a sig-
niﬁcant overlap with the schizophrenia ﬁngerprint (Figure 3b).
This included proteins such as SYT2, septin 2 (SEPT2),
syntaxin-binding protein 1 (STXBP1) and calreticulin (CALR).
Validation experiments. Considering the impairment of
synaptic transmission associated with MDD, as observed
here and previously,
1,4 we carried out technical validation of
three such differentially expressed candidate proteins
identiﬁed by the shotgun LC-MS
E molecular proﬁling
method. Using Western blot, we analyzed the proteins
AMPH and GAP43 in whole tissue lysates as well as with
SRM-MS to validate the differential expression of SNAP25.
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binding protein-1 (HINT1) in MDD,
39,40 we also carried out
SRM-MS experiments for this protein. Apart from GAP43,
differential expression of all of these proteins was validated
(Figure 4). Of note, AMPH was only found to be signiﬁcant in
the MDD-NP versus MDD-P comparison with a fold change
of 1.13 based on MS proﬁling and Western blot analysis
revealed that this was increased by 1.47 fold in all MDD
patients. This lends support to our choice of a cutoff of 1.15-
fold in the LC-MS
E screening phase and also suggests that
the quantiﬁcation of label-free proteomics data may
underestimate fold changes, as demonstrated previously.
29
The results also suggested that the oxidative phosphoryla-
tionpathwaywasdysregulatedinMDDthroughthedifferential
expression of several subunits of the mitochondrial com-
plexes (Supplementary Material 6). Therefore, we carried out
a functional validation experiment of whole tissue lysates to
test this possibility by measuring the levels of ATP in the
DLPFC samples. This analysis showed that lower levels of
ATP were observed in MDD tissues compared with controls,
although this was not related to psychotic status (Figure 4).
Discussion
This is the ﬁrst shotgun proteomics study of brain tissue
samples from MDD patients. We employed an LC-MS
E
method in combination with gel-based protein fractionation
to increase proteome coverage, including the identiﬁcation of
membrane proteins,
26 which are mediators of signal trans-
duction and potential therapeutic targets. We also applied LC-
SRM-MS for the ﬁrst time in proteome studies of psychiatric
disorders. This method was used here as a means of
validating differences in the levels of identiﬁed proteins with
greater level of sensitivity and speciﬁcity compared to the
conventional LC-MS
E proﬁling. The multiplex nature of SRM
allowstheaccuratequantiﬁcationoftensofproteinsinasingle
experimental run allowing its use in both pre-clinical and
clinical trials as well as in clinical pipelines for detection of
Table 2 Differentially expressed proteins in all post mortem brains from MDD patients compared with controls
Biological processes Gene name Protein name FC IP P-value q-value
Metabolism/energy ACOT13 Acyl coenzyme A thioesterase 1.62 2 0.0445 0.3665
ACYP2 Acylphosphatase 2 1.34 3 0.0107 0.3248
COX4I1 Cytochrome c oxidase subunit 4 isoform 1 mitochondrial 1.24 5 0.0311 0.3248
COX5B Cytochrome c oxidase subunit 5B mitochondrial 1.44 6 0.0210 0.3665
COX7A2 Cytochrome c oxidase polypeptide 7A2 mitochondrial 1.31 2 0.0325 0.4368
CYCS Cytochrome c 1.51 13 0.0311 0.3248
NDUFA13 NADH dehydrogenase Ubiquinone 1-alpha subcomplex subunit 13 1.43 7 0.0248 0.3248
NDUFA2 NADH dehydrogenase Ubiquinone 1-alpha subcomplex subunit 2 1.39 3 0.0349 0.3665
NDUFA6 NADH dehydrogenase Ubiquinone 1 alpha subcomplex subunit 6 1.62 5 0.0025 0.2412
NDUFS5 NADH dehydrogenase Ubiquinone iron-sulphur protein 5 1.57 2 0.0393 0.3665
UQCRFSL1 Cytochrome b c1 complex subunit 1.38 2 0.0433 0.3665
Transport/energy ATP5I ATP synthase subunit e mitochondrial 1.37 4 0.0410 0.3248
ATP5L ATP synthase subunit g mitochondrial short ATPase 1.34 4 0.0370 0.3248
Transport APOE Apolipoprotein E 1.17 4 0.0279 0.3356
FABP3 Fatty acid-binding protein heart 1.62 7 0.0219 0.3248
FABP7 Fatty acid-binding protein brain 1.35 4 0.0444 0.3665
FXYD6 FXYD domain containing ion transport regulator 6 1.76 4 0.0008 0.3665
GABARAPL2 Gamma aminobutyric acid receptor-associated protein-like 2 1.44 3 0.0318 0.3665
HRSP12 Ribonuclease UK114 1.25 7 0.0270 0.3248
SNAP25 Synaptosomal-associated protein 25  1.15 26 0.0070 0.1247
Cell communication
and signalling
AMPH
a Amphiphysin 1.13 41 0.0379 0.1347
DPYSL2 Dihydropyrimidinase-related protein 2 1.17 10 0.0027 0.3248
DPYSL3 Dihydropyrimidinase-related protein 3 1.16 2 0.0124 0.3665
FKBP2 FK506-binding protein 2 1.30 3 0.0072 0.3665
GAP43 Neuromodulin; growth-associated protein 43 1.20 27 0.0302 0.1247
HINT1 Histidine triad nucleotide-binding protein 1 1.59 4 0.0038 0.2412
RHOC Rho-related GTP-binding protein 1.49 2 0.0095 0.3665
Cell growth and
maintenance
MAP1LC3A Microtubule-associated proteins 1A 1B light chain 3A 1.30 5 0.0455 0.3248
PFN1 Proﬁlin-1 1.42 6 0.0259 0.3248
PFN2 Proﬁlin 2 1.46 7 0.0032 0.3248
TUBA4B Putative tubulin-like protein alpha-4B 1.19 6 0.0238 0.3248
Protein metabolism CST3 Cystatin C 1.68 3 0.0284 0.3356
CSTB Cystatin-B 1.29 2 0.0208 0.3665
SNCA Alpha synuclein 1.51 5 0.0382 0.3248
SNCG Gamma synuclein 1.38 11 0.0074 0.3248
Regulation of nucleic acid
metabolism
HIST4H4 Histone H4 1.44 5 0.0265 0.3248
SATB2 DNA-binding protein SATB2 1.35 3 0.0314 0.3248
SSBP1 ss DNA-binding protein mitochondrial short Mt SSB 1.56 2 0.0397 0.4368
Unknown CISD1 CDGSH iron sulfur domain-containing protein 1  1.34 8 0.0140 0.3248
Abbreviations: FC, fold change; IP, number of identiﬁed peptides; MDD, major depressive disorder.
P-values for Wilcoxon test.
aAMPH is an exception for the fold change cutoff because it has been validated by Western blot.
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GAP43 could not be validated most probably due to the
different sensitivity of mass spectrometry and Western blot.
41
One of the major pathways associated with the DLPFC
proteomic differences in MDD patients was related to energy
metabolism, consistent with previous imaging ﬁndings. Pre-
vious studies have shown a reduction in glucose metabolism
in brains from MDD patients using a positron emission
tomography approach.
42 This is interesting as an increase in
glucose metabolism was found in this same brain region of
MDD patients after administration of the anti-depressant
paroxetine.
43 Such effects on energy are likely to be common
in psychiatric disorders,
44 suggesting that these may be
nonspeciﬁc features of these conditions. However, our data
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Proteomic analysis of depression brains
D Martins-de-Souza et al
6
Translational PsychiatryTable 3 Differentially expressed proteins comparing healthy controls to MDD patients divided in psychotic or non-psychotic patients
Biological processes Gene name Protein name FC IP P-value q-value
(a) MDD-NP vs controls
Cell growth/maintenance TUBA4A Tubulin alpha-4A chain 2.03 2 0.0321 0.3725
TUBA4B Putative tubulin-like protein alpha-4B 1.33 6 0.0196 0.3725
Cell communication/signalling HINT1 Histidine triad nucleotide-binding protein 1 1.45 4 0.0063 0.3725
RHOC Rho-related GTP-binding protein RhoC 1.36 2 0.0396 0.3725
SIRPA Tyrosine protein phosphatase non receptor
type substrate 1
1.19 12 0.0293 0.3154
Metabolism/energy ATP5F1 ATP synthase subunit b mitochondrial 1.24 3 0.0245 0.3154
ATP5I ATP synthase subunit e mitochondrial 1.58 3 0.0237 0.3725
COX7A2 Cytochrome c oxidase polypeptide 7A2
mitochondrial
1.55 2 0.0007 0.3725
CYCS Cytochrome c 1.59 13 0.0001 0.3725
NDUFA2 NADH dehydrogenase ubiquinone 1 alpha
subcomplex subunit2
1.60 3 0.0401 0.3725
NDUFS5 NADH dehydrogenase ubiquinone iron sulfur
protein 5
1.67 2 0.0257 0.3725
Protein metabolism CST3 Cystatin C 1.58 3 0.0333 0.3725
HSP90AA1 Heat-shock protein HSP 90-alpha 1.22 5 0.0327 0.3725
PPIA Peptidyl-prolyl cis-trans isomerase A 1.37 3 0.0265 0.3725
SNCG Gamma synuclein 1.38 11 0.0215 0.3725
Transport FABP3 Fatty acid-binding protein heart 1.45 6 0.0028 0.3725
FXYD6 FXYD domain-containing ion transport
regulator 6
1.77 4 0.0039 0.3725
Unknown CISD1 CDGSH iron sulfur domain-containing
protein 1
1.64 8 0.0134 0.3725
(b) MDD-P vs controls
Metabolism/energy TXN Thioredoxin  1.33 3 0.0005 0.2854
MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  1.45 2 0.0448 0.3654
ACYP2 Acylphosphatase 2  1.47 3 0.0344 0.2854
COX5B Cytochrome c oxidase subunit 5B
mitochondrial
 1.56 7 0.0453 0.2854
PRDX6 Peroxiredoxin-6, mitochondrial  1.60 5 0.0169 0.2854
NDUFA13 NADH dehydrogenase ubiquinone 1 alpha
subcomplex subunit 13
 1.61 7 0.0477 0.2854
NDUFA6 NADH dehydrogenase ubiquinone 1 alpha
subcomplex subunit 6
 1.71 5 0.0022 0.2854
ACOT13 Acyl coenzyme A thioesterase 13 Short Acyl
CoA thioesterase 13
 1.88 2 0.0207 0.2854
ATP6V1F V type proton ATPase subunit F Short V
ATPase subunit F
 2.26 2 0.0492 0.2854
Cell growth/maintenance TUBB2A Tubulin beta-2A chain 1.58 2 0.0428 0.2854
TUBB6 Tubulin beta-6 chain  1.24 5 0.0179 0.3654
NEFM Neuroﬁlament medium polypeptide  1.31 143 0.0079 0.1236
PFN2 Proﬁlin 2  1.58 7 0.0209 0.2854
SEPT2 Septin 2 1.25 20 0.0016 0.3298
PFN1 Proﬁlin-1  1.59 6 0.0239 0.2655
Transport ATP6V1H V type proton ATPase subunit H Short V
ATPase subunit H
 1.15 24 0.0052 0.3654
SNAP25 Synaptosomal-associated protein 25 1.17 27 0.0048 0.2655
FABP7 Fatty acid-binding protein brain  1.47 4 0.0393 0.2854
GABARAPL2 Gamma aminobutyric acid receptor-
associated protein-like 2
 1.72 3 0.0275 0.2854
FABP3 Fatty acid-binding protein heart  1.85 6 0.0371 0.2854
Cell communication/signalling AMPH Amphiphysin  1.16 40 0.0068 0.3024
FKBP1A Peptidyl prolyl cis-trans isomerise  1.51 2 0.0230 0.4132
RHOC Rho-related GTP-binding protein RhoC  1.63 2 0.0413 0.2854
CALM1 Calmodulin  1.66 2 0.0275 0.2854
Protein metabolism PPIA Peptidyl-prolyl cis-trans isomerase A 1.29 11 0.0123 0.3298
SNCG Gamma synuclein  1.37 11 0.0107 0.2655
SNCA Alpha synuclein  1.58 5 0.0235 0.2854
CSTB Cystatin-B  1.70 2 0.0474 0.4132
CST3 Cystatin C  1.81 3 0.0357 0.2655
Regulation of nucleic acid metabolism PBXIP1 Pre B-cell leukemia transcription factor-
interacting protein 1
 1.31 2 0.0123 0.3298
SATB2 DNA-binding protein SATB2  1.64 3 0.0018 0.2854
HIST1H2BL Histone H2B type 1-L  1.85 2 0.0412 0.4132
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Translational Psychiatrysuggest some speciﬁcity in energy metabolism dysfunction at
the protein level. Although in schizophrenia the main affected
metabolic pathway appears to be glycolysis,
38 the most
affected pathway in MDD appeared to be oxidative phospho-
rylation. However, it should be noted that some components
of the oxidative phosphorylation pathway are also affected in
schizophrenia,
45,46 but not to the same extent as glycolysis.
We found that 20 different subunits of the oxidative
phosphorylation complexes showed increased levels in
MDD brains (Supplementary Material 6). Interestingly, oxida-
tive phosphorylation proteins are mostly decreased in
schizophrenia.
37 Considering that the main product of
oxidative phosphorylation is ATP, we measured ATP con-
centrations in MDD DLPFC samples and veriﬁed that there
were signiﬁcantly lower levels in comparison with those found
in control subjects (Figure 4). One possible explanation for
this is that ATP may be depleted in this brain area of MDD
subjects due to the presence of oxidative stress
47 and the
oxidative phosphorylation complexes may be over-expressed
to compensate for this effect.
Our ﬁndings also support an impairment of synaptic
function in MDD, especially for components of soluble
N-ethylmaleimidesensitive (NSF) sensitive factor attachment
proteinreceptor(SNARE)function.Forexample,weidentiﬁed
and validated changes in SNAP25, which is a pre-synaptic
membrane protein involved in anchoring synaptic vesicles in
the SNARE complex. We also found changes in the
GABARAPL2, a cytosolic regulator of SNAREs involved in
stimulation of the ATPase activity of NSF that signals
disassembly and recycling of SNARE complexes.
48 Syntaxin
1B (STX1B), which was found signiﬁcantly upregulated
(P¼0.0291, fold change 1.07), but discarded from our list
Table 3 (Continued)
Biological processes Gene name Protein name FC IP P-value q-value
SSBP1 Single-stranded DNA-binding protein
mitochondrial
 1.99 2 0.0269 0.4132
HIST1H4A Histone H4  2.11 4 0.0314 0.2854
Unknown FANCI Fanconi anemia group I protein  1.42 2 0.0314 0.3298
SVIP Small VCP p97-interacting protein  1.43 2 0.0121 0.4132
(c) MDD-P vs MDD-NP
Cell communication/signalling ARF1 ADP-ribosylation factor 1 1.37 8 0.0119 0.3001
ARF3 ADP-ribosylation factor 3 1.69 8 0.0163 0.3001
EEF1AL3 Putative elongation factor 1-alpha-like 3  1.16 11 0.0031 0.3612
FKBP1A Peptidyl prolyl cis-trans isomerase  1.45 2 0.0414 0.4091
PRKCA Protein kinase C alpha type 1.32 2 0.0101 0.3579
SIRPA Tyrosine protein phosphatase non receptor
type substrate 1
1.24 12 0.0135 0.3248
STIP1 Stress-induced phosphoprotein 1 1.58 2 0.0252 0.3579
SYT2 Synaptotagmin 2 2.10 4 0.0113 0.3579
Cell growth/maintenance SEPT2 Septin 2 1.33 20 0.0417 0.2311
TUBA1B Tubulin alpha-1B chain 1.15 17 0.0314 0.3001
TUBA3E Tubulin alpha-3E chain 1.15 22 0.0026 0.2311
TUBA8 Tubulin alpha-8 chain 2.57 3 0.0389 0.4091
TUBB2A Tubulin beta-2A chain 1.93 2 0.0366 0.3001
TUBB8 Tubulin beta-8 chain B 1.30 2 0.0291 0.3579
Metabolism/energy SDHA Succinate dehydrogenase, mitochondrial 1.68 3 0.0095 0.3579
DLAT Dihydrolipoyllysine acetyltransferase 1.39 14 0.0057 0.3248
TXN Thioredoxin  1.79 3 0.0416 0.4091
ATP6V1A V-type proton ATPase catalytic subunit A 1.24 17 0.0057 0.3248
Protein metabolism CALR Calreticulin  1.26 2 0.0314 0.3612
SERPINB1 Leukocyte elastase inhibitor  1.42 3 0.0222 0.3579
PPIA Peptidyl-prolyl cis-trans isomerase A 1.36 11 0.0291 0.3001
UBE2V2 Ubiquitin-conjugating enzyme E2 variant 2  2.57 2 0.0155 0.4091
Transport SLC25A12 Calcium-binding mitochondrial carrier protein
Aralar1
1.83 18 0.0086 0.3248
GOSR1 Golgi SNAP receptor complex member 1 1.36 2 0.0321 0.3579
STXBP1 Syntaxin-binding protein 1 1.44 112 0.0002 0.1214
Regulation of nucleic acid metabolism PAPOLA Poly A polymerase alpha  1.32 2 0.0399 0.3579
Unknown FMNL2 Formin-like protein 2 1.83 2 0.0185 0.3579
NCDN Neurochondrin 1.25 20 0.0072 0.3248
SAMD9 Sterilealphamotifdomain-containingprotein9  1.42 4 0.0241 0.3579
SASS6 Spindle assembly abnormal protein 6
homolog
1.60 2 0.0467 0.4091
Abbreviations: Acc No, SwissProt accession number; FC, fold change; IP, number of identiﬁed peptides; MDD, major depressive disorder.
In gene name, italic/underline means the proteins that were also found differentially expressed comparing all MDD patients with all controls of this study as shown in
Table 1. In bold, are proteins previously found in proteome analyses of schizophrenia. P-values for Wilcoxon test.
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transport vesicles (Figure 1), which inhibits SNARE func-
tion
49,50 and thereby controls neurotransmitter release.
51
STX1B has a role in the calcium-dependent synaptic
transmission
52 and has also been found to be increased in
schizophrenia.
53 Changes were also found and validated for
AMPH, which is present on the cytoplasmic surface of
synaptic vesicles.
54 In addition, we found alterations in
alpha-synuclein (SNCA) and SNCG, which are involved in
integration of presynaptic signaling and membrane trafﬁcking.
SEPT2
TUBB2A
SIRPA
SYT2
TUBA1B
ATP6V1A
CALR
STXBP1
MDD-P vs MDD-NP
SCZ vs control
Previously published
22 other 
proteins
SEPT2
TUBB2A
COX5B
PRDX6
NDUFA6
ATP6V1F
TUBB6
NEFM
CALM1
CST3
FABP3
RHOC
SNCG
PPIA
MDD-NP vs control
MDD-P vs control SCZ vs control
Previously published
13 other 
proteins
22 other 
proteins
Figure 3 Venn diagrams representing (a) overlaps of differentially expressed proteins in MDD with and without psychosis versus controls; (b) overlaps of differentially
expressed proteins between MDD with psychosis versus MDD without psychosis. The overlaps of differentially expressed proteins with previous analyses of schizophrenia
DLPFC tissue are also indicated. DLPFC, dorsolateral prefrontal cortex; MDD, major depressive disorder.
Figure 4 Validation of differentially expressed proteins and metabolites in the DLPFC from MDD patients and controls using different techniques as described. P values
were obtained by Student’s t-test statistical analysis. Differences with Po0.05 were considered signiﬁcant. DLPFC, dorsolateral prefrontal cortex; FC, fold change; MDD,
major depressive disorder.
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previously with Parkinson’s and Alzheimer’s diseases.
55
Dysregulation of phospholipids and fatty acids, which are
critical components of synaptic vesicle membranes, has also
been linked to depression.
56 Our proteomic ﬁndings identiﬁed
changes in expression of arachidonic acid and phospholipase
D2(PLD2),whicharecomponentsinmembranestructureand
function. Antidepressant treatment reduces arachidonic acid
turnover,
57 and the release of this molecule is decreased
when PLD2 is inactivated.
58 In this regard, we found that the
levels of SNCA were increased, which inhibits PLD2. More-
over, PLD2 is inhibited by AMPH,
59 which was found to be
increased. PLD2 interacts directly with protein kinase C
(PKC).PKCisacomponentofintracellularsignaltransduction
andits activityhasbeen shown tobereduced indepression.
60
PKCisalsoactivatedinthecytoplasmbydiacylglycerol,whichis
anchoredin themembrane,facilitating PKCtranslocationfrom
the cytosol to membranes. Diacylglycerol and inositol trispho-
sphate are hydrolytic products of membrane phospholipid
phosphatidyl inositol-bisphosphate resulting from activity of
the enzyme phospholipase C. In this study, we found changes
in several proteins in MDD brains, which are involved in
PKC regulation, including PFN1, PFN2 and actin-binding
proteins
61 (Figure 1).
We found that the levels of HINT1 were increased in MDD
patients, which was conﬁrmed by SRM mass spectrometry
analysis. Interestingly, the levels of this protein were found to
be deceased in the DLPFC in previous studies of schizo-
phrenia.
62 HINT1 was originally described as a PKC inhibitor,
although its precise function has yet to be conﬁrmed. It is
widely expressedin anumberof tissuesincluding liver,kidney
and brain, where it has been associated with control of
transcriptional processes along with tumor suppression and
susceptibility.
63 A potential role of HINT1 in MDD and anxiety
disorders was described recently from studies of Hint1
knockout (KO) mice. The absence of HINT1 expression
resulted in altered postsynaptic dopamine transmission in
striatum and nucleus accumbens as well as an elevation of
circulating corticosterone levels, suggesting effects on the
hypothalamic-pituitary-adrenal axis. In addition, anxiety-like
behavior has been observed in this model.
39,40,64 Ourﬁndings
not only support those of previous studies, which suggested
that HINT1 may be a novel biomarker for MDD, but suggest
that this could be speciﬁc for subjects without associated
psychosis. This was shown by the fact that this protein was
only increased in those MDD subjects without psychosis.
It has been known for decades that most neuropsychiatric
disorders have a signiﬁcant overlap of symptoms. It is likely
that this will be reﬂected by an overlap of molecules and
pathways in affected tissues such as the brain and only subtle
differences are likely to be responsible for differentiating one
disorder from another. For example, psychotic symptoms,
which are a hallmark for schizophrenia, may occur in the
course of MDD, although in a slightly different manner. Even
so, the current ﬁndings suggest that there may be common
molecular changes in MDD-P and patients with schizophre-
nia. In all, 11 of the 36 differentially expressed proteins in
DLPFC of MDD-P patients compared with controls were
identiﬁed in previous studies of schizophrenia.
38,65,66 This
included calmodulin (CALM1), which is involved in synaptic
metabolism and calcium homeostasis and regulates the
function of D1 and D2 dopamine receptors
67 and the
neuroﬁlament medium polypeptide (NEFM), which belongs
to the dopamine receptor-interacting protein (DRIP) family of
proteins.
67 Another protein that was altered in common
between MDD-P and schizophrenia subjects was peroxi-
redoxin-6 (PRDX6).
66,68 This protein has been associated
with schizophrenia susceptibility in Taiwanese families
69 and
has a role in phospholipid metabolism with phospholipase A2
(PLA2) activity.
The identiﬁcation of proteome ﬁngerprints has the potential
to lead to the development of more speciﬁc classiﬁcation tests
compared with those depending on single molecules. In this
case, testing for correlative changes in these protein ﬁnger-
prints in peripheral tissues such asCSF and even serum might
lead to the development of multiplex biomarker assays for
psychosis. Moreover, direct comparison of MDD-P and MDD-
NP patients resulted in identiﬁcation of 12 differentially
expressed proteins, which have also been found previously in
schizophrenia (Table 3c). It was also of interest that compar-
ison of MDD-P patients to controls identiﬁed differentially
expressed proteins that were associated with energy metabo-
lism, whereas comparison of MDD-NP patients and controls
resultedinidentiﬁcationofproteins,whichweremostlyinvolved
in cell growth and maintenance. This suggested that different
mechanisms may be involved in the development of these two
forms of MDD. Further experiments in this area should be
conducted,which mayeventuallyhelpwithpatientstratiﬁcation
for generating more personalized treatments.
Interestingly, 53.7% of the altered proteins in MDD-P
overlapped with those in total MDD patients. This suggests
that there may be a proteomic signature in MDD that exists
independent of the presence of psychosis. Of the proteins
unique to the MDD-P patients, two could not be associated
with a biological class, although there are some leads about
their function. One of these proteins was fanconi anemia
group I protein (FANCI) that participates in protein ubiquitina-
tion and its differential expression can lead to defective DNA
repair.
70 The other was small VCP p97-interacting protein
(SVIP), which is an 8.5 KDa membrane protein involved in
ubiquitination of endoplasmic reticulum misfolded proteins.
71
Considering the novelty of these proteins in psychiatric
studies and their role in ubiquitination, their function could
be further investigated in MDD-P.
Curiously, none of the proteins that were found to be
differentially expressed between MDD-P and MDD-NP
patients were altered in total MDD patients. This suggested
that the MDD-P vs MDD-NP signature was more strongly
relatedtopsychosisandalsomore similartopreviousﬁndings
in schizophrenia brain proteomes. In the MDD-P and MDD-
NP comparison, we also identiﬁed protein targets with
unknown biological function such as formin-like protein 2
(FMNL2), sterile alpha motif domain-containing protein 9
(SAMD9), spindle assembly abnormal protein 6 homolog
(SASS6) and neurochondrin (NCDN). NCDN seems to
interact with phosphatidic acid, which is a metabolite related
to phospholipid metabolism (Figure 1) and SASS6 is likely to
be involved in ubiquitination.
72
One protein changed in common in all comparisons shown
in Table 3 was PPIA (also known as cyclophilin A). PPIA
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cyclosporin A-mediated immunosuppression.
73 Interestingly,
this protein has also been found to be increased in
schizophrenia thalamus,
38 which suggests some relationship
with the psychosis status. However, considering the fact that
this protein is also differentially expressed in MDD-NP
compared with controls, it does not seem to be a speciﬁc
biomarker candidate to psychosis, but most likely associated
to psychiatric conditions. On the other hand, the protein
peptidylprolyl cis-trans isomerase (FKBP1A), which is from
the same family of PPIA, was speciﬁcally altered in MDD-P
samples. FKBP1A acts on immunoregulation and cellular
processes involved in protein folding and trafﬁcking and it also
interacts with several intracellular signal transduction pro-
teins.
74 Moreover, FKBP1A binds to the immunosuppres-
sants FK506 and rapamycin. Interestingly, the mammalian
target of rapamycin (mTOR) signaling pathway in the
prefrontal cortex is compromised in MDD,
75 and mTOR
interacts with FKBP1A bound to rapamycin.
76 FKBP1A also
interacts with the transforming growth factor (TGF)-beta
receptor, which is critical for modulation of GABA synaptic
transmissionanddendritichomeostasis.
77Moreover,FMNL2,
which we also found increased in MDD-P, is also part of TGF-
beta pathway.
78 These ﬁndings warrant further studies on the
involvement of these proteins in psychiatric disorders.
Figure 2 represents a broader perspective of the unique
ﬁndings of each of the compared groups. Changes in energy
metabolism are notable in both MDD-P and MDD-NP.
Although protein metabolism processes are more related to
MDD-NP, changes in cell growth/maintenance, transport and
regulation of nucleic acids are more related to MDD-P. When
the two groups of MDD patients are compared, defects in cell
signaling are pronounced so as are proteins with unknown
biological processes. This last group of proteins should be
furtherstudiedforprovidingmoreleadsaboutthestratiﬁcation
of different MDD subtypes.
It is widely known that factors such as age, gender,
postmortem interval, drug treatment and others may have
confounding effects on global proteomic studies involving
post-mortem samples.
79 None of the factors considered here
seem to have had a signiﬁcant effect on the analyses.
Compared groups are matched for demographic variables
and these have not shown signiﬁcant differences (Table 1). In
addition, no unusual segregation of subjects using principle
component analyses has been observed (Supplementary
material 3). However, it should be noted that information was
not available regarding the number of patients who were
relapsedorwhowereonor offmedicationatthe timeofdeath.
Although some effects on proteomic changes were observed
when comparing MDD patients that committed suicide
(n¼17) with non-suicide MDD patients (n¼6), we could not
explore this any further due to the low numbers of subjects
who did not die from suicide. Moreover, in the non-suicide
group, some of these subjects actually attempted suicide
although they were not successful.
The static nature of post-mortem brain tissue and limited
sample sizes can be a drawback in studies such as the one
presented here. Therefore, a replication of this study in an
independent sample would be essential. However, we concur
with a recent report that the analysis of post-mortem tissue
from patients in brain disorders is indispensable, especially
considering that it has generated important and unique
insights for psychiatric studies.
80
Our systems biology analyses of the MDD brain proteome
showed that some of the differentially expressed proteins
found in subjects with MDD have been associated previously
with other diseases such as Huntington’s and Alzheimer’s
disease and schizophrenia. This supports the notion that
neurological and psychiatric disorders may share common
pathways at the molecular level. Therefore, identiﬁcation of
multiple components of these conditions may be required in
order to identify unique biomarker ﬁngerprints. This may
require identiﬁcation of differences in the expression of
several genes and proteins, together with consideration of
potential environmental factors. Nevertheless, we and others
have identiﬁed peculiarities for different diseases, as seen by
differential expression of speciﬁc proteins. In fact, we showed
that the changes in HINT1 expression were speciﬁc for MDD-
NP in the DLPFC. Moreover, there appears to be distinct
energy metabolism signatures for MDD and schizophrenia,
with MDD affected more by changes in oxidative phosphor-
ylation and schizophrenia through glycolysis-related path-
ways.
The current ﬁndings support the known impairment on
synaptic transmission and especially on SNARE-related
proteins in MDD. We also attempted to identify biomarker-
speciﬁc signatures for subgroups of MDD through studies on
depression associated with psychosis and even with suicide.
Interestingly, we found a signiﬁcant overlap of differentially
expressed proteins in post-mortem brain tissue from MDD
subjects with psychosis, with that of schizophrenia subjects.
Theseﬁndingssuggestthatitmaybepossibletodistinguish
different subtypes of MDD patients based on differences in
brain proteomic proﬁles. Translating such ﬁndings to the
periphery might lead to novel personalized medicine strate-
gies based on patient stratiﬁcation according to molecular
proﬁles. Also, the identiﬁcation of new models for MDD based
on brain and serum molecular proﬁles could lead to the
development of such models for use in drug discovery. This
couldleadtomoretargetedtreatmentapproachesandreduce
the rate of drug attrition within the ﬁeld of neuropsychiatric
disorders.
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